Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats.

Autor: Gruen ME; Translational Research in Pain (TRiP) Program, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.; Behavioral Medicine, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.; Comparative Pain Research and Education Center, North Carolina State University, Raleigh, North Carolina, USA., Myers JAE; Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, Michigan, USA., Tena JS; Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, Michigan, USA., Becskei C; Veterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium., Cleaver DM; Veterinary Medicine Research and Development, Zoetis Inc, Kalamazoo, Michigan, USA., Lascelles BDX; Translational Research in Pain (TRiP) Program, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.; Comparative Pain Research and Education Center, North Carolina State University, Raleigh, North Carolina, USA.; Thurston Arthritis Center, UNC School of Medicine, Chapel Hill, North Carolina, USA.; Center for Translational Pain Research, Department of Anesthesiology, Duke University, Durham, North Carolina, USA.
Jazyk: angličtina
Zdroj: Journal of veterinary internal medicine [J Vet Intern Med] 2021 Nov; Vol. 35 (6), pp. 2752-2762. Date of Electronic Publication: 2021 Nov 01.
DOI: 10.1111/jvim.16291
Abstrakt: Background: Frunevetmab, a felinized antinerve growth factor monoclonal antibody, effectively decreases osteoarthritis (OA) pain in cats.
Objective: To evaluate the efficacy of frunevetmab given at monthly intervals in a randomized, placebo-controlled, parallel-group, double-blind superiority study.
Animals: Two hundred seventy-five client-owned cats with naturally-occurring OA pain and associated mobility impairment and disability.
Methods: Randomized, placebo-controlled, parallel-group, double-blind, superiority study. Following screening, cats received frunevetmab (nominal dose of 1.0 mg/kg, SC [effective dose range of 1.0-2.8 mg/kg]) or placebo on days 0, 28, and 56. Outcome measures were owner questionnaires and veterinary physical and orthopedic evaluations at days 28, 56, and 84. Success/failure rates (and numbers needed treat, NNT) and change in scores (and standardized effect size, ES) were analyzed.
Results: Frunevetmab (182) and placebo (93) treated cats were enrolled and received at least 1 treatment. Significant improvement with frunevetmab over placebo occurred at days 28 and 56 for the client specific outcome measures (CSOM) questionnaire (success rates and total scores [NNT of 9 and ES of 0.3 at day 56]); at days 28 and 56 for owner-assessed global treatment response; and at days 56 and 84 for veterinarian-assessed joint pain (ES of 0.18 at day 56). Adverse events did not differ between groups, except skin disorders which collectively occurred significantly more frequently in frunevetmab treated (32/182 cats) vs placebo (8/93 cats).
Conclusions and Clinical Importance: Frunevetmab has the potential to address a critical gap in the treatment of pain because of osteoarthritis in cats.
(© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)
Databáze: MEDLINE
Externí odkaz: